---
title: "Johnson & Johnson (JNJ) Plans $1 Billion Sale of ‘Cerenovus’ Stroke Unit"
date: "2025-02-12 04:31:39"
summary: "Pharmaceutical giant Johnson &amp; Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion or more. Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor..."
categories:
  - "tipranks"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2025/02/aaa-34-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Pharmaceutical giant Johnson & Johnson [(JNJ)](https://www.tipranks.com/stocks/jnj) is planning to [sell its stroke care business](https://www.tipranks.com/news/the-fly/jj-puts-stroke-care-unit-up-for-sale-ft-reports) called “Cerenovus” for $1 billion or more.

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

*The Financial Times* is reporting that the sale is part of Johnson & Johnson’s [ongoing efforts to restructure](https://www.tipranks.com/news/jnj-earnings-johnson-johnsons-cancer-drugs-and-medtech-power-q4-revenues) its medical technology division. The company is seeking a valuation of between $1 billion and $1.5 billion for the Cerenovus sale.

Cerenovus makes surgical equipment for use on medical patients who have suffered a stroke. The business unit has reportedly been presented to potential private equity and strategic buyers by senior management of Johnson & Johnson. It’s not clear how much interest, if any, there has been from potential buyers.

Internal Restructuring
----------------------

The sale of Cerenovus comes as Johnson & Johnson undertakes a multi-year internal restructuring following the Covid-19 pandemic. Over the last three years, the pharma giant has spent more than $30 billion to acquire several [medical device makers](https://www.tipranks.com/news/johnson-johnsons-nasal-spray-gets-fda-nod-as-depression-treatment).

At the same time, the company has determined that it would be prudent to offload the Cerenovus surgical equipment business as part of its restructuring. Johnson & Johnson has struggled as sales of the company’s Covid-19 treatments has waned.

[JNJ stock has risen only 2%](https://www.tipranks.com/stocks/jnj) over the last 12 months, underperforming the broader market.

**Is JNJ Stock a Buy?**
-----------------------

The stock of Johnson & Johnson has a consensus Moderate Buy rating among 14 Wall Street analysts. That rating is based on six Buy and eight Hold recommendations issued in the last three months. The [average JNJ price target](https://www.tipranks.com/stocks/jnj/forecast) of $167.50 implies 7.18% upside from current levels.

[![](https://blog.tipranks.com/wp-content/uploads/2025/02/image-451-1024x813.png)](https://www.tipranks.com/stocks/jnj/forecast)

**[Read more analyst ratings on JNJ stock](https://www.tipranks.com/stocks/jnj/forecast)**

[tipranks](https://tipranks.com/news/johnson-johnson-jnj-plans-1-billion-sale-of-cerenovus-unit)
